Best Topical Antimicrobials for Foot Ulcers: A Practical Wound Care Guide

Foot ulcers, especially diabetic foot ulcers (DFUs), are prone to high bacterial load, biofilm, and recurrent contamination. Topical antimicrobials can be useful tools in the wound-care toolbox: they may reduce local bioburden, help control odor, and support wound-bed preparation when used appropriately. However, they are an adjunct, not a substitute, for good wound bed preparation (debridement), offloading, vascular optimization, and, when needed, systemic antibiotics for true infection.

This guide explains the main topical antimicrobial options for foot ulcers, what the evidence says about each, practical indications and cautions, and how to integrate topical agents into an overall treatment strategy.

When to consider topical antimicrobials for a foot ulcer

Topical antimicrobials are usually considered when one or more of the following is true:

• The wound shows local high bioburden without systemic infection signs (e.g., heavy exudate, malodor, stalled healing suspected due to colonization or biofilm).

• The wound is malodorous and odor control is a priority for patient comfort or quality of life.

• You need a short-term adjunct while other measures are optimized (debridement, moisture balance, offloading, perfusion).

• There are local signs of infection but systemic antibiotics are being planned or while culture results are pending—topical measures may be used adjunctively, not as sole therapy in severe infections.

Topical agents are not generally recommended as a replacement for systemic therapy when there are clear signs of invasive infection (spreading cellulitis, systemic toxicity, osteomyelitis). Use topical antimicrobials as part of an overall wound-care plan.

Key topical antimicrobial options: what they are and what evidence exists

Below are the main topical antimicrobials used in foot ulcer care, with practical notes and supporting evidence.

1) Cadexomer iodine (CIOD)

What it is: Cadexomer iodine is an iodine-containing formulation in a bead or ointment matrix that slowly releases iodine and also absorbs exudate and slough. It combines antiseptic action with some physical wound-cleansing effect.

Evidence and uses: Multiple systematic reviews and meta-analyses suggest cadexomer iodine can reduce slough and bacterial load and may accelerate granulation and wound-size reduction compared with standard care in some chronic wounds. CIOD is commonly used in wounds with slough, moderate exudate, or where bioburden control is needed as part of wound bed preparation. Use cautiously in patients with iodine allergy or thyroid disease.

Practical tip: Apply per product instructions, reassess frequently, and combine CIOD with debridement and exudate management.

2) Topical metronidazole

What it is: Metronidazole applied as a topical gel, spray, or powder targets anaerobic bacteria and is widely reported to reduce malodor and anaerobic-driven drainage in chronic wounds.

Evidence and uses: Systematic reviews and clinical reports find that topical metronidazole reduces wound odor and may improve local wound appearance; most studies are small and short-term but consistently show benefit for odor control. Topical metronidazole is an accepted option for malodorous wounds and can be used while other wound-care measures are performed. It’s generally used as a local adjunct rather than sole therapy for invasive infection.

Practical tip: Use topical metronidazole for short courses targeted at odor or local anaerobic overgrowth, and monitor wound response.

3) Silver-containing dressings and topical silver

What it is: Silver-impregnated dressings or topical silver formulations release ionic silver that has broad-spectrum antimicrobial activity.

Evidence and uses: Reviews and trials have produced mixed results over time. Older Cochrane and systematic reviews found limited high-quality evidence for universal benefit; more recent data suggest silver dressings may reduce bacterial load and, in some settings, improve healing or reduce time to closure—particularly in infected or heavily colonized wounds—though results vary by product and clinical context. For DFUs, several studies support use of silver dressings for bioburden control; however, they are an adjunct and should be used within stewardship principles.

Practical tip: Choose silver dressings when you need a broad-spectrum topical agent for heavily colonized wounds, and reassess frequently. Avoid long-term, indiscriminate use to limit resistance and cost.

4) Medical-grade honey

What it is: Sterile, medical-grade honey (often Manuka-based) has osmotic, low-pH, and antibacterial properties, and may also support autolytic debridement.

Evidence and uses: Several meta-analyses and trials suggest honey can accelerate healing and reduce infection parameters in some DFUs and chronic wounds, with benefits for granulation and reduced pain in reports. Evidence quality varies; honey may be a reasonable option for infected or contaminated DFUs where dressings with antimicrobial properties are desired.

Practical tip: Use certified medical-grade honey preparations (not raw honey), watch for pain on application in some wounds, and consider allergy history.

5) Polyhexamethylene biguanide (PHMB)

What it is: PHMB is a polymeric antiseptic used in dressings and topical solutions that has activity against a range of bacteria and biofilm.

Evidence and uses: Reviews and clinical summaries show PHMB can reduce bacterial burden, help manage biofilm, and in some studies promoted healing and reduced pain. PHMB is commonly used as a topical antiseptic within a broader wound-care regimen and is considered by many wound-care services as a biofilm-management adjunct.

Practical tip: PHMB products can be used as irrigants or within dressings. Follow product instructions and reassess progress.

6) Other topical antibiotics and antiseptics

• Mupirocin: Useful for superficial Staph carriage (e.g., nasal or limited skin) but topical antibiotics for open foot ulcers are used selectively; deep infection needs systemic therapy.

• Povidone-iodine: Effective antiseptic but can be cytotoxic in some contexts; cadexomer iodine is often preferred as it releases iodine slowly and helps debride.

• Hypochlorous acid / sodium hypochlorite (dilute): Used as antiseptic irrigants with variable evidence; can help reduce surface bioburden.

Practical tip: Reserve topical antibiotics for targeted indications and avoid routine prolonged use to limit resistance.

Biofilm, topical agents, and the role of mechanical disruption

Biofilms are a major reason topical agents alone sometimes fail. Biofilm-embedded bacteria tolerate antimicrobials; mechanical disruption (sharp debridement, hydrosurgery, or ultrasound) to remove biofilm and devitalized tissue is often required before topical antimicrobials can have their best effect. Many consensus documents emphasize combining debridement with topical antimicrobials and dressings targeted to exudate and tissue type.

Practical algorithm for using topical antimicrobials on foot ulcers

1. Assess: Confirm wound type, exudate level, perfusion, neuropathy, and systemic signs. If systemic infection or osteomyelitis is suspected, prioritize systemic therapy and surgical consultation.

2. Debride: Remove devitalized tissue and disrupt biofilm where safe and feasible.

3. Select topical agent based on problem:

   • Malodor/anaerobes → topical metronidazole.

   • Thick slough / need for antiseptic and exudate control → cadexomer iodine.

   • Heavy bioburden, suspected resistant organisms, or broad-spectrum need → silver or PHMB dressings.

   • When gentle antimicrobial plus healing promotion is desired → medical-grade honey.

4. Use as adjunct: Combine topical antimicrobial with appropriate dressing for exudate control and injury protection. Reassess frequently (often every 48–72 hours initially in heavily exuding or infected wounds).

5. Stop or change if no improvement in a defined time (e.g., 1–2 weeks) or if clinical deterioration occurs. Escalate to systemic therapy when invasive infection is present.

Safety, stewardship, and practical cautions

• Avoid routine, prolonged use of topical antimicrobials without reassessment. Overuse can be costly and may select for resistance or interfere with healing if agents are cytotoxic.

• Monitor for local irritation or allergy (iodine sensitivity, honey allergy).

• Culture wisely: superficial swabs often reflect surface contamination; when therapy will be guided by microbiology, obtain deep tissue or bone samples after debridement where possible.

• Combine with non-antimicrobial measures (offloading, revascularization, glycemic control, nutrition) — topical antimicrobials rarely fix the underlying causes alone.

What the guidelines say

Recent international guidelines for diabetic foot infection and wound management stress that topical agents can be useful adjuncts for local bioburden and odor control, but systemic antibiotics are required for invasive infection. The IWGDF/IDSA guidance and contemporary reviews recommend using topical antimicrobials as part of a broader, evidence-based wound-care pathway that prioritizes debridement, perfusion, and infection severity assessment.

Bottom line

Topical antimicrobials are valuable adjuncts for managing local bioburden, biofilm, and odor in foot ulcers when used thoughtfully and combined with debridement, exudate control, and optimization of systemic and mechanical factors. Cadexomer iodine, topical metronidazole, silver dressings, medical-grade honey, and PHMB are the most commonly used topical options; each with strengths, typical indications, and limitations supported by varying levels of evidence. Use them selectively, reassess frequently, and escalate to systemic therapy when clinical signs indicate invasive infection.

See also

How to Tell If a Wound Is Healing: Signs of Proper Wound Care Progress
Best Practices for Chronic Wound Care: How to Assess Foot Ulcers Effectively
Why Diabetic Foot Wounds Heal Slowly: Top Factors That Delay Recovery
How Often Should Wound Dressings Be Changed? Best Practices for Healing
Best Wound Dressings for High-Exudate Wounds

More Information

For more information on the latest effective wound care, contact us to set up a time for a call.

Sources

1. Dumville JC, et al. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2017. (Systematic review covering many topical agents). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481886/ PMC

2. Senneville E, et al. 2023. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes. International Working Group on the Diabetic Foot (IWGDF/IDSA). https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-04-Infection-Guideline.pdf.

3. Woo K, Dowsett C, Costa B, Ebohon S, Woodmansey EJ, Malone M. Efficacy of topical cadexomer iodine treatment in chronic wounds: Systematic review and meta-analysis of comparative clinical trials. International Wound Journal. 2021 Oct;18(5):586-597. doi: 10.1111/iwj.13560. Epub 2021 Feb 8. PMID: 33559332; PMCID: PMC8450789.
   https://pubmed.ncbi.nlm.nih.gov/33559332/

4. Gethin G, Vellinga A, McIntosh C, Sezgin D, Probst S, Murphy L, Carr P, Ivory J, Cunningham S, Oommen AM, Joshi L, Ffrench C. Systematic review of topical interventions for the management of odour in patients with chronic or malignant fungating wounds. Journal of Tissue Viability. 2023 Feb;32(1):151-157. doi: 10.1016/j.jtv.2022.10.007. Epub 2022 Nov 9. PMID: 36376189.

   https://www.sciencedirect.com/science/article/abs/pii/S0965206X22001152?via%3Dihub

5. Yildiz Karadeniz E, Kaplan Serin E. Use of honey in diabetic foot ulcer: Systematic review and meta-analysis. Journal of Tissue Viability. 2023 May;32(2):270-278. doi: 10.1016/j.jtv.2023.03.002. Epub 2023 Mar 23. Erratum in: J Tissue Viability. 2023 Aug;32(3):449. doi: 10.1016/j.jtv.2023.05.001. PMID: 37032304.
   https://pubmed.ncbi.nlm.nih.gov/37032304/

6. To E, Dyck R, Gerber S, Kadavil S, Woo KY. The Effectiveness of Topical Polyhexamethylene Biguanide (PHMB) Agents for the Treatment of Chronic Wounds: A Systematic Review. Surgical Technology International. 2016 Oct 26;29:45-51. PMID: 27608742.
   https://pubmed.ncbi.nlm.nih.gov/27608742/

7. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C; DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabetic Medicine. 2006 Apr;23(4):348-59. doi: 10.1111/j.1464-5491.2006.01785.x. PMID: 16620262.
   https://pubmed.ncbi.nlm.nih.gov/16620262/

8. Schaper N, et al. 2023. IWGDF Guidelines on the prevention and management of diabetes-related foot disease. International Working Group on the Diabetic Foot.
   https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-Guidelines-2023.pdf.

9. Paul JC, Pieper BA. Topical metronidazole for the treatment of wound odor: a review of the literature. Ostomy Wound Manage. 2008 Mar;54(3):18-27; quiz 28-9. PMID: 18382045.
   https://pubmed.ncbi.nlm.nih.gov/18382045/

10. Radhakkrishnan R, et al. 2019. Review: Treating Chronic Ulcers with Cadexomer Iodine. WoundsSource. https://www.woundsource.com/blog/review-treating-chronic-ulcers-cadexomer-iodine.

11. Huang, Chunhua PhDa; Wang, Ruiqi MDb; Yan, Zhangren PhDa,∗. Silver dressing in the treatment of diabetic foot: A protocol for systematic review and meta-analysis. Medicine 100(7):p e24876, February 19, 2021. | DOI: 10.1097/MD.0000000000024876 Lippincott. https://journals.lww.com/md-journal/fulltext/2021/02190/silver_dressing_in_the_treatment_of_diabetic_foot_.103.aspx

12. 2020. Evidence Summary: Polyhexamethylene biguanide for chronic wounds. Wound Healing and Management Unit, Curtin University.
    https://journals.cambridgemedia.com.au/application/files/2416/0749/9088/WPR_284_ES-_Polyhexamethylene_biguanide.pdf

13. IWGDF Guidelines on the prevention and management of diabetic foot disease. 2019. International Working Group on the Diabetic Foot.
    https://iwgdfguidelines.org/wp-content/uploads/2019/05/IWGDF-Guidelines-2019.pdf.

14. University of Illinois Chicago DIG Pharmacy FAQ. How should metronidazole be used for chronic wound odor? https://dig.pharmacy.uic.edu/faqs/2025-2/april-2025-faqs/how-should-metronidazole-be-used-for-chronic-wound-odor/

15. ScienceDirect topic — Cadexomer iodine overview.
    https://www.sciencedirect.com/topics/medicine-and-dentistry/cadexomer-iodine.

16. Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005082. DOI: 10.1002/14651858.CD005082.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005082.pub2/

17. Holubová A, Chlupáčová L, Krocová J, Cetlová L, Peters LJF, Cremers NAJ, Pokorná A. The Use of Medical Grade Honey on Infected Chronic Diabetic Foot Ulcers—A Prospective Case-Control Study. Antibiotics. 2023; 12(9):1364. https://doi.org/10.3390/antibiotics12091364
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10525154/

18. Rippon MG, Rogers AA, Ousey K. Polyhexamethylene biguanide and its antimicrobial role in wound healing: a narrative review. Journal of Wound Care. 2023 Jan 2;32(1):5-20. doi: 10.12968/jowc.2023.32.1.5. PMID: 36630111. https://pubmed.ncbi.nlm.nih.gov/36630111/

19. Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD011038. DOI: 10.1002/14651858.CD011038.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011038.pub2/information/id.

20. Gupta S, et al. 2022. Comparison of the Outcomes of Cadexomer Iodine and Povidone-Iodine Ointments in Wound Management. Cureus Journal of Medical Science.
    https://www.cureus.com/articles/95924-comparison-of-the-outcomes-of-cadexomer-iodine-and-povidone-iodine-ointments-in-wound-management.

21. Nascimento JWA do, et al. Efficacy of medical grade honey in the treatment of diabetic foot ulcers: a systematic review. Research, Society and Development. DOI: https://doi.org/10.33448/rsd-v11i4.27839
    https://rsdjournal.org/rsd/article/view/27839. rsdjournal.org

22. Castiello G, et al. 2023. Efficacy of Polyhexamethylene Biguanide in Reducing Post-Operative Infections: A Systematic Review and Meta-Analysis. Pub: Surgical Infections.
    https://www.liebertpub.com/doi/10.1089/sur.2023.199.

* This blog is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.